Answers are grounded in this paper and cite their sources.
State-of-the-art review shows ABO-incompatible heart transplantation reduces infant wait times, indicating noninferior survival compared to matched donors.
In the 1990s, neonates born with severe congenital heart disease faced more than 50% mortality awaiting an ABO-compatible (ABOc) transplant donor. This desperate situation, together with knowledge of gaps in the adaptive immune system in early childhood, led to the clinical exploration of intentional ABO-incompatible (ABOi) heart transplantation. In 2001, West et al. reported the first series of 10 infants in Canada. Since then, consideration of ABOi heart donors has become the standard of care for children awaiting transplantation in the first few years of life, resulting in reduced wait times and better organ utilization with noninferior post-transplant outcomes compared to ABOc recipients. This state-of-the-art review discusses the clinical development and evolution, underlying and resulting immunological aspects, current challenges, and future directions of ABOi heart transplantation.
No takes yet. Share an insight, caveat, or question.
Bansal et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: